Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02608268
Title Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Advanced Solid Tumor

Therapies

Spartalizumab

Sabatolimab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.